



# PERIT-PD Study Newsletter

Welcome to our monthly newsletter

Issue 1

*Valentine's Day Special*

February 2017

## Study news

A very warm thank you for your participation in PERIT-PD, which is entering its 9<sup>th</sup> and final year of recruitment.



It started in Cardiff in September 2008, with sites around the UK joining from April 2014. We now have more than 20 sites all over the country helping us collect peritonitis samples.

A special mention of 2 new sites which just joined: St Helier Hospital in Surrey and Peterborough City Hospital. We look forward to working with you.

The recruitment has been quiet in the last few months and around Christmas time so we need a final push to reach our target number of 400. We will let you know about the study recruitment figures in this monthly newsletter.

## In this issue:

- ✦ Study news
- ✦ Latest Recruitment data
- ✦ Publications
- ✦ Study background
- ✦ PERIT-PD in numbers

## Publications

Samples from PERIT-PD have already helped advance our understanding of infection responses in peritoneal dialysis patients. Led by Matthias Eberl in Cardiff University, researchers have shown the importance of novel types of T cells in response to infection, and in subsequent changes to the peritoneal membrane.

*Liuzzi AR et al.: Unconventional human T cells accumulate at the site of infection in response to microbial ligands and induce local tissue remodeling. J Immunol. 2016;197:2195-207.*

If you would like to know more about the ongoing research, please visit:  
<http://www.cardiff.ac.uk/research/explore/research-units/peritoneal-immunity-group>  
or contact Dr Eberl at [eberlm@cf.ac.uk](mailto:eberlm@cf.ac.uk).

Recruitment data	December 2016	January 2017
Inverness	2	2
Cardiff	2	
Newcastle		2
Bradford		1

# Study background

The “Achilles’ heel” of PD remains the susceptibility to recurrent infection with detrimental effects on the process of dialysis through direct membrane damage, but also in more severe infection through significant morbidity and mortality.

Over the past decade there has been a shift in infection profiles towards more virulent infections and an increased prevalence of antibiotic resistance. This, together with the already unacceptable cure and relapse rates, and concomitant morbidity and mortality represent significant limitations to PD therapy.


As we approach the post-antibiotic era there is a clear need for novel therapies to fight infections by resistant strains and improve patient outcomes. If we are to limit the susceptibility to infection and the detrimental impact of prolonged inflammation on membrane longevity, we need to better understand the processes causing deleterious alterations to the peritoneal immune response.

The peritoneal cavity in PD serves as unique window to inflammatory scenarios that can be prospectively observed *in vivo*. It affords easy, continuous access to all relevant cellular and humoral players, and allows us to examine how treatment and infection modulate these processes. We know of no other experimental model that gives such direct insight into human immune responses in a similarly clinically relevant, convenient, non-invasive manner.


We are hoping that PERIT-PD will help understand some of those processes.

## PERIT-PD in numbers

Help us reach our 400 Target



### PERIT-PD recruitment



Top recruiters since 2014	
Cardiff	30
Leeds	17
Brighton	10
Inverness	11
Sheffield	9
Wolverhampton	9

## Information about PERIT-PD

<http://kidneyresearchunit.wales/en/perit-pd-study.htm>

Follow the above link for our FAQ

## Contact

Dr Chantal Colmont

Email: colmontcs@cf.ac.uk

Tel: 02920 748469